AZD0240 / AstraZeneca - LARVOL DELTA

Pre-clinical characterization of AZD0240, a CRISPR-engineered autologous TCR-T cell product targeting KRAS-G12D/HLA-A*11:01 that is multi-armored to increase epitope sensitivity (AACR 2025) - "Notably, the armored AZD0240 T cells were unable to respond to the KRAS G12 wild-type epitope, and no signs of increased TCR cross- or allo-reactivity, or malignant transformation were detected, derisking the clinical use of this armoring strategy. Taken together, AZD0240 is a KRAS-G12D/HLA-A*11:01 targeted TCR-T cell therapy that employs a novel multi-armoring strategy and is currently in preparation for clinical testing, with encouraging signs of pre-clinical efficacy and safety."

Preclinical • Colorectal Cancer • Oncology • Pancreatic Cancer • Solid Tumor • KRAS